Most doctors surveyed plan no change to Iclusig prescriptions: JPMorgan

|By:, SA News Editor

Strength in shares of Ariad Pharmaceuticals (ARIA +8.9%) has held up well throughout the session.

From the JPMorgan note which sparked the rally: "The majority of docs we surveyed who have used Iclusig do not expect their use to change over the next 6-12 months [and] somewhat surprisingly, there were more docs who expect to increase their use of the drug vs. docs who expect use to decrease."

As noted earlier, this would seem to suggest that investor concern over a recent FDA drug safety communication (see here and here) may be overblown.

As for comparisons between Iclusig and Novartis' (NVS +1.4%) Tasigna, JPM says "only 4% of docs view Iclusig’s safety profile as 'significantly worse' than Tasigna" (52% of Iclusig-prescribing docs characterize the drug's safety profile is "moderately worse").